

# **Growth Strategy Gains Momentum**

**Terumo Corporation  
President & Representative Director  
Yutaro Shintaku**

**July 28, 2011**

# Hands-on Approach for Unifying CaridianBCT

project **UNITE** 夢  
Creating Value through Innovation and Integration - Together




# New Opportunities with BCT Technologies

The first autologous cellular immunotherapy (Cancer vaccine) in business

<Example: Prostate cancer>

U.S. cancer vaccine company  
FDA approval in Apr, 2010



CaridianBCT  
Spectra®



Collect blood containing  
lots of immune cells

Derive dendritic  
cells from blood

Introduce antigen onto  
dendritic cells, then grow

Administer to  
the patients

Potential application toward other cancers

# Further Potential




Cell Expansion



Therapeutic Aphaeresis

Cellular Immunotherapy



Myocardial patch

Myocardial Regeneration

Utilizing cells and growth factors,  
into  
Regenerative Medicine



Cell deriving



Treatment of coronary ischemia  
& Chronic limb ischemia



# *IR Contact*

---

## **TERUMO Corporation**

**Corporate Communication (IR) Dept.**

**E-mail: [kouhou\\_terumo01@terumo.co.jp](mailto:kouhou_terumo01@terumo.co.jp)**

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.